NASDAQ : FATE
Fate Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 2.17 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 260.01M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 242.64M |
| Enterprise Value | 164.54M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 119.82M |
| Shares Outstanding | 119.82M |
| Shares Change (YoY) | +1.19% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 0.99% |
| Owned by Institutions (%) | 58.75% |
| Float | 105.75M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 37.57 |
| Forward PS | 51.60 |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.59 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 25.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.85 |
| Quick Ratio | 4.75 |
| Debt / Equity | 0.49 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -60.75% |
| Return on Assets (ROA) | -26.22% |
| Return on Invested Capital (ROIC) | -28.96% |
| Return on Capital Employed (ROCE) | -58.23% |
| Weighted Average Cost of Capital (WACC) | 13.85% |
| Revenue Per Employee | $40,317 |
| Profits Per Employee | -$782,584 |
| Employee Count | 161 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.53 |
| 52-Week Price Change | +50.74% |
| 50-Day Moving Average | 2.28 |
| 200-Day Moving Average | 1.96 |
| Relative Strength Index (RSI) | 42.86 |
| Average Volume (20 Days) | 1,141,566 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 10.62M |
| Short Previous Month | 10.76M |
| Short % of Shares Out | 8.86% |
| Short % of Float | 10.04% |
| Short Ratio (days to cover) | 6.60 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 6.49M |
| Gross Profit | -77.93M |
| Operating Income | -132.49M |
| Pretax Income | -126.00M |
| Net Income | -126.00M |
| EBITDA | -120.50M |
| EBIT | -132.49M |
| Loss Per Share | -$1.05 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 153.77M |
| Total Debt | 75.68M |
| Net Cash | 78.10M |
| Net Cash Per Share | $0.65 |
| Equity (Book Value) | 153.44M |
| Book Value Per Share | 1.31 |
| Working Capital | 125.36M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -101.94M |
| Capital Expenditures | -3.71M |
| Depreciation & Amortization | 11.99M |
| Net Borrowing | n/a |
| Free Cash Flow | -105.66M |
| FCF Per Share | -$0.88 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -2,041.13% |
| Pretax Margin | -1,941.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.19% |
| Shareholder Yield | -1.19% |
| Earnings Yield | -51.99% |
| FCF Yield | -43.33% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $5.74 |
| Price Target Difference | 183.65% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | -15.51% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -8.8 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |